Treat-and-extend Using Aflibercept for Type 3 Neovascularization
Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
Type 3 neovascularization is a subtype of neovascular age-related macular degeneration (AMD)
that is characterized by intraretinal neovascularization. Treat-and-extend (TAE) regimen is a
widely-used, effective anti-vascular endothelial growth factor treatment regimen for
neovascular AMD, regardless of subtypes of AMD. The purpose of the present study is to
investigate the 18-month treatment outcome of TAE in type 3 neovascularization.